PLACE OF CHOLINOLYTICS IN ARRESTING THE ABDOMINAL PAIN IN THE FUNCTIONAL GASTROINTESTINAL DISORDERS


如何引用文章

全文:

详细

The article discusses the potentials for use of different cholinolytics, including hyoscine butylbromide (Buscopan), for the treatment of chronic abdominal pain in functional gastrointestinal disorders. It is emphasized that the Buscopan with proven efficacy and safety profile is indicated for patients with functional gastrointestinal disorders, accompanied by smooth muscle spasms; Buscopan has a pronounced antispasmodic effect at the first stage of contraction of muscle fiber, relieves abdominal pain, reduces the secretion of digestive glands, does not have central anticholinergic action and is well tolerated during long-term use.

参考

  1. Thompson WG, Longstreth GF, Drossman DA, et al. Functional bowel disoders and functional abdominal pain. Gut 1999;45(2):43-7.
  2. Camilleri M. Review article: clinical evidence to support current therapies of irritable bowel syndrome. Aliment Pharmacol Ther 1999;13(2):48-53.
  3. Corazziari E, Shaffer EA, Hogan WJ, et al. Functional disoders of the biliary tract and pancreas. Gut 1999;45(2):48-54.
  4. Drossman DA. Review article: an integrated approach to the irritable bowel syndrome. Aliment Pharmacol Ther 1999;13(2):3-14.
  5. Costa M, Simon JH. The Enteric Nervous System. Amer J Gastroenterol 1994;89(8):129-37.
  6. Kamm MA, Lennard-Jones J. Constipation. Wrightson Biomedical Publishing LTD, 1994:402.
  7. Gershon MD. Review article: roles played 5-hydroxytryptamine in the physiology of the bowel. Aliment Pharmacol Ther 1999;13(2):15-30.
  8. Malagelada JR. Review article: clinical pharmacology models of irritable bowel syndrome. Aliment Pharmacol Ther 1999;13(2):57-64.
  9. Sanger GJ. S-hydroxytryptamine and functional bowel disoders. Neurpgastroenterol Motil 1996;8:319-31.
  10. American College of Gastroenterology. ACD Task Force jn IBS recommendations. Am J Gastroenterol 2009;104;1-35.
  11. Poynard T, Regimbeau C, Benhamou Y. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2001;15(3):355-61.
  12. Ihsii M, Kurachi Y. Мускариновые рецепторы ацетилхолина. Curr Pharmaceut Design 2006;12(28):3573-81.
  13. Коротько Г.Ф. Секреция поджелудочной железы. Краснодар, 2005. 311 с.
  14. Tytgat G. Hyoscine butylbromide: a review of its use in the treatment of abdominal cramping and pain. Drugs 2007;67(9):1343-57.
  15. Kitzing J, Therapy of abdominal complaints suspected to be of biliary origin. Z Gastroenterol 1976;14(8):752-55.
  16. Allescher Н, Neuhause Н, Hagenmuller F, Classen M. Effect of N-Butylscopolamine on Sphincter of Oddi Motility in Patients during Routine ERCP-a Manometric Study. Endoscopy 1990;22:160-63.
  17. Maitai C, Njoroge D, Munenge R. A comparative study of two antispasmodic products: Buscopan and NO-Spa. East Afr Med J 1985;62(7):480-85.
  18. Khalif I, Quigley E, Makarchyk P, et al. Interaction between Symptoms and Motor and Visceral Sensory Responses of Irritable Bowel Syndrome Patients to Spasmolytics (Antispasmodics). J Gastrointestin Liver Dis 2009;18(1):17-22.
  19. Mueller-Lissner S. Placebo- and paracetamol-controlled study on the efficacy and
  20. tolerability of hyoscine butylbromide in the treatment of patients with recurrent crampy abdominal pain. Aliment Pharmacol Ther 2006;23:1741-48.
  21. Mertz H. How effective are oral hyoscine butilbromide and paracetemol for the relief of crampy abdominal pain? Nat Clin Pract Gastroenterol Hepatol 2007;4(1):10-11.
  22. Poynard T, Regimbeau C, Benhamou Y. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2001;15:355-361.
  23. Мишуровская Т.С., Белоусова Е.А., Коротько Г.Ф. Возможности гиосцина бутил-бромида (Бускопана) при лечении больных хроническим панкреатитом // Фарматека 2009. № 13. С. 45-49.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2012
##common.cookie##